Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Affinivax, Inc.

http://affinivax.com/

Latest From Affinivax, Inc.

Dealmaking Quarterly Statistics, Q2 2022

During Q2, biopharma merger and acquisition value reached $25.4bn and drew in $27.3bn in potential deal value from alliances. Device company M&A values reached $2.7bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $534.3m.

Commercial Deals

‘New GSK’ Raises Outlook After Shingrix Hits New Heights

The company looks to be building momentum at last, with four more late-stage trial readouts expected in the second half of 2022.

Sales & Earnings Companies

GSK Spies Pfizer Challenge With $2.1bn Vaccine Company Acquisition

GSK has spotted an opportunity to challenge Pfizer’s blockbuster Prevnar franchise, but the potential of Affinivax’s platform has yet to be proven.

Commercial Companies

Keeping Track: Breakthroughs Of Summer Break Ground In Psychiatry, Cancer (Especially Nasopharygeal Cancer) And Vaccines

US FDA’s marquee expedited review program added 15 new breakthrough therapy designations between June and August.

US FDA Performance Tracker Review Pathway
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Vaccines
UsernamePublicRestriction

Register